ORASURE TECHNOLOGIES INC Form 8-K November 29, 2011

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-K

#### **CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(d) OF THE

**SECURITIES EXCHANGE ACT OF 1934** 

Date of Report (Date of earliest event reported): November 29, 2011

# OraSure Technologies, Inc.

(Exact Name of Registrant as Specified in Charter)


Delaware (State or Other Jurisdiction

001-16537 (Commission 36-4370966 (I.R.S. Employer

of Incorporation) File Number) Identification No.)

#### 220 East First Street

Bethlehem, Pennsylvania (Address of Principal Executive Offices) Registrant s telephone number, including area code: 610-882-1820 18015-1360 (Zip Code)



- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 7.01 Regulation FD Disclosure.

On November 29, 2011, the Company issued a press release announcing the receipt from the U.S. Food and Drug Administration of a waiver under the Clinical Laboratory Improvement Amendments of 1988 ( CLIA ) for the Company s OraQhiHCV rapid antibody test. A copy of the press release is attached as Exhibit 99 to this Form 8-K and is incorporated herein by reference.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99	Press Release, dated November 29, 2011, announcing receipt of a CLIA waiver for the Company s OraQuic® HCV rapid antibody test.

#### **Signatures**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

OraSure Technologies, Inc.

Date: November 29, 2011

By: /s/ Jack E. Jerrett
Jack E. Jerrett
Senior Vice President, General Counsel and Secretary

# **Index to Exhibits**

Exhibit No.	Description
99	Press Release, dated November 29, 2011, announcing receipt of a CLIA waiver for the Company s OraQuic® HCV rapid antibody test.